Published in Antimicrob Agents Chemother on May 01, 1988
Fluoroquinolone antimicrobial agents. Clin Microbiol Rev (1989) 6.45
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob Agents Chemother (1994) 1.15
Human serum enhances the postantibiotic effect of fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.09
In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone. Antimicrob Agents Chemother (1991) 1.04
In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea. Antimicrob Agents Chemother (1989) 1.02
Mechanism of action of lomefloxacin. Antimicrob Agents Chemother (1990) 0.97
Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother (1994) 0.96
Comparative in vitro and in vivo activities of six new monofluoroquinolone and difluoroquinolone 3-carboxylic acids with a 7-azetidin ring substituent. Antimicrob Agents Chemother (1990) 0.96
Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1990) 0.90
Concentrations of oral lomefloxacin in serum and bronchial mucosa. Antimicrob Agents Chemother (1990) 0.85
In vitro susceptibilities of Pseudomonas pseudomallei to 27 antimicrobial agents. Antimicrob Agents Chemother (1990) 0.85
Treatment of acute uncomplicated urinary tract infections with 3 days of lomefloxacin compared with treatment with 3 days of norfloxacin. Antimicrob Agents Chemother (1993) 0.81
Pharmacokinetics of lomefloxacin in healthy volunteers: comparison of 400 milligrams once daily and 200 milligrams twice daily given orally for 5 days. Antimicrob Agents Chemother (1990) 0.80
Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections. Antimicrob Agents Chemother (1992) 0.76
Pharmacokinetics of lomefloxacin in renally compromised patients. Antimicrob Agents Chemother (1990) 0.75
Intraprostatic distribution of lomefloxacin following multiple-dose administration. Antimicrob Agents Chemother (1990) 0.75
The beta-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol (1973) 25.78
Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother (1980) 23.54
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone. Antimicrob Agents Chemother (1986) 3.98
In vitro and in vivo activity of NY-198, a new difluorinated quinolone. Antimicrob Agents Chemother (1987) 3.84
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin. Drugs Exp Clin Res (1985) 1.40
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. Antimicrob Agents Chemother (1978) 4.74
LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. Antimicrob Agents Chemother (1979) 4.52
Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother (1978) 3.68
In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother (1997) 3.22
Local surveillance of antimicrobial resistance. Synercid Resistance Surveillance Group. Lancet (1998) 2.60
In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin. Antimicrob Agents Chemother (1978) 2.58
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother (1980) 2.51
In vitro activity of Ro 15-8074 and Ro 19-5247, two orally administered cephalosporin metabolites. Antimicrob Agents Chemother (1986) 2.45
Comparison of the modified Stokes' method of susceptibility testing with results obtained using MIC methods and British Society of Antimicrobial Chemotherapy breakpoints. J Antimicrob Chemother (1998) 2.42
A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother (1997) 2.37
Clavulanic acid and CP-45,899: a comparison of their in vitro activity in combination with penicillins. J Antimicrob Chemother (1980) 2.35
Low muscle mass and sarcopenia: common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther (2015) 2.34
Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J (1990) 2.33
Comparative pharmacokinetics and tissue penetration of sulbactam and ampicillin after concurrent intravenous administration. Antimicrob Agents Chemother (1982) 2.12
In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother (1990) 2.09
In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother (1988) 2.09
Comparison of the in vitro activity of Bay k 4999 and piperacillin, two new antipseudomonal broad-spectrum penicillins, with other beta-lactam drugs. Antimicrob Agents Chemother (1978) 2.07
In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents. Antimicrob Agents Chemother (1986) 2.04
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother (1984) 2.01
Lower motor neuron degeneration associated with type C RNA virus infection in mice: neuropathological features. J Neuropathol Exp Neurol (1974) 2.00
Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents against Chlamydia trachomatis. Eur J Clin Microbiol (1987) 1.93
Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother (1980) 1.87
The comparative pharmacokinetics of five quinolones. J Antimicrob Chemother (1986) 1.86
Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother (1988) 1.85
Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J Antimicrob Chemother (1991) 1.85
The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin. J Antimicrob Chemother (1989) 1.75
Temocillin, in-vitro activity and the pharmacokinetics and tissue penetration in healthy volunteers. J Antimicrob Chemother (1982) 1.70
Ro 13-9904: A cephalosporin with a high degree of activity and broad antibacterial activity: an invitro comparative study. J Antimicrob Chemother (1980) 1.68
The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother (1994) 1.68
N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother (1981) 1.65
Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother (1991) 1.63
Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219). Antimicrob Agents Chemother (1996) 1.63
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin. Antimicrob Agents Chemother (1992) 1.62
SQ 26,776, a novel beta-lactam: an in-vitro comparison with other antimicrobial agents. J Antimicrob Chemother (1981) 1.60
The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. J Antimicrob Chemother (1999) 1.58
Cefixime, in-vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother (1989) 1.57
International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother (1983) 1.52
Evaluation of a novel solid-phase immunoassay, Clearview Chlamydia, for the rapid detection of Chlamydia trachomatis. J Clin Microbiol (1990) 1.51
Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother (1999) 1.50
Ultrastructural studies of multiple sclerosis. Lab Invest (1969) 1.49
Sch 29482--a novel penem antibiotic: an in-vitro comparison of its activity with other beta-lactams. J Antimicrob Chemother (1982) 1.49
Serological characterization of HTLV-III infection in AIDS and related disorders. J Infect Dis (1986) 1.47
Pharmacokinetics and tissue penetration of azthreonam. Antimicrob Agents Chemother (1982) 1.42
Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics. Antimicrob Agents Chemother (1983) 1.42
Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. Clin Endocrinol (Oxf) (1996) 1.40
Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother (2002) 1.40
The concentration of sparfloxacin in lung tissues after single and multiple oral doses. Int J Antimicrob Agents (1994) 1.38
Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother (2001) 1.38
Problems with Iso-Sensitest agar. J Antimicrob Chemother (1990) 1.38
The in-vitro activity of a new highly active quinolone, DU-6859a. J Antimicrob Chemother (1993) 1.38
The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent. J Antimicrob Chemother (1998) 1.37
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother (1993) 1.37
Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother (1998) 1.33
Comparison of sensititre dried microtitration trays with a standard agar method for determination of minimum inhibitory concentrations of antimicrobial agents. Antimicrob Agents Chemother (1980) 1.30
Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa. Thorax (1988) 1.29
The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother (2002) 1.27
6-beta-bromo- and 6-beta-iodo penicillanic acid, two novel beta-lactamase inhibitors. J Antimicrob Chemother (1981) 1.27
In vitro activities of two glycylcyclines. Antimicrob Agents Chemother (1994) 1.27
Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother (1995) 1.25
Study of regressing warts by immunofluorescence. Lancet (1973) 1.25
Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir Med (1993) 1.24
Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother (1995) 1.22
Human T-cell lymphotropic virus type 1 Tax mediates enhanced transcription in CD4+ T lymphocytes. J Virol (1996) 1.22
The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother (1998) 1.22
Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J Antimicrob Chemother (1988) 1.21
In vitro activity of CGP 31608, a new penem. Antimicrob Agents Chemother (1987) 1.21
Sterile pyuria and Chlamydia trachomatis. Lancet (1990) 1.20
Pharmacokinetics and tissue penetration of cefepime. J Antimicrob Chemother (1989) 1.19
A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose. J Antimicrob Chemother (1999) 1.19
The adjusted serum calcium concept--a reappraisal. Ann Clin Biochem (1986) 1.18
Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Rev Infect Dis (1988) 1.18
Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax (1990) 1.18
Microlavage: a technique for determining the volume of epithelial lining fluid. Thorax (1991) 1.18
The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone. J Antimicrob Chemother (1993) 1.17
In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother (1992) 1.17
Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent. J Antimicrob Chemother (1991) 1.16
The in-vitro activity of Ro 17-2301, a new monobactam, compared with other antimicrobial agents. J Antimicrob Chemother (1985) 1.16
"Pathologic" fractures: should these be included in epidemiologic studies of osteoporotic fractures? Osteoporos Int (2009) 1.16
Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther (2013) 1.15
The in vitro activity of ABT773, a new ketolide antimicrobial agent. J Antimicrob Chemother (2000) 1.14
In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrob Agents Chemother (2002) 1.14
The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur Respir J (1994) 1.14